Azurity Company Profile

✉ Email this page to a colleague

AZURITY has thirty-eight approved drugs.

There are ninety-five US patents protecting AZURITY drugs. There is one tentative approval on AZURITY drugs.

There are three hundred and forty-four patent family members on AZURITY drugs in forty-eight countries and forty-three supplementary protection certificates in fifteen countries.

International Patents:	344
US Patents:	95
Tradenames:	37
Ingredients:	29
NDAs:	38
Patent Litigation for Azurity:	See patent lawsuits for Azurity

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	EDARBYCLOR	azilsartan kamedoxomil; chlorthalidone	TABLET;ORAL	202331-001	Dec 20, 2011		RX	Yes	No	9,066,936	⤷ Subscribe	Y			⤷ Subscribe
Azurity	XATMEP	methotrexate sodium	SOLUTION;ORAL	208400-001	Apr 25, 2017		RX	Yes	Yes	11,116,724	⤷ Subscribe				⤷ Subscribe
Azurity	ERY-TAB	erythromycin	TABLET, DELAYED RELEASE;ORAL	062298-001	Approved Prior to Jan 1, 1982	AB	RX	No	No		⤷ Subscribe				⤷ Subscribe
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-003	Jan 30, 2019		DISCN	Yes	No	10,130,580	⤷ Subscribe	Y			⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Azurity	VERELAN PM	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020943-003	Nov 25, 1998	4,863,742	⤷ Subscribe
Azurity	EDARBI	azilsartan kamedoxomil	TABLET;ORAL	200796-001	Feb 25, 2011	5,736,555	⤷ Subscribe
Azurity	NYMALIZE	nimodipine	SOLUTION;ORAL	203340-002	Apr 8, 2020	8,517,997	⤷ Subscribe
Azurity	VERELAN	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019614-001	May 29, 1990	4,863,742	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	300 mg	➤ Subscribe	2006-05-19
➤ Subscribe	Oral Solution	1 mg/mL	➤ Subscribe	2018-08-31
➤ Subscribe	Extended-release Tablets	100 mg and 200 mg	➤ Subscribe	2006-07-20
➤ Subscribe	Powder for Oral Solution	1 mg/mL	➤ Subscribe	2016-06-21

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1718641	1290016-3	Sweden	⤷ Subscribe	PRODUCT NAME: AZILSARTANMEDOXOMIL OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV, INKLUDERANDE KALIUMSALT; REG. NO/DATE: EU/1/11/735/001 20111207
1718641	121 5004-2012	Slovakia	⤷ Subscribe	PRODUCT NAME: AZILSARTAN MEDOXOMIL; REGISTRATION NO/DATE: EU/1/11/734/001 - EU/1/11/735/011 20111207
1718641	12C0034	France	⤷ Subscribe	PRODUCT NAME: AZILSARTAN MEDOXOMIL ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/735/001 20111207
1718641	C20120005 00053	Estonia	⤷ Subscribe	PRODUCT NAME: IPREZIV - ASILSARTAANMEDOKSOMIIL;REG NO/DATE: C(2011) 9281 FINAL 07.12.2011
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.